A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Wyeth is now a wholly owned subsidiary of Pfizer
United States: Food and Drug Administration
|Philadelphia, Pennsylvania 19104|
|Nashville, Tennessee 37203-1632|
|Lebanon, New Hampshire|